{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005904","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.179111+00:00","generated_at":"2026-06-05T08:34:34.364591+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Zevra Therapeutics amends bylaws to address universal proxy rules and update stockholder meeting procedures","bullets":["Board approved amended and restated bylaws effective February 22, 2024.","Amendments incorporate SEC universal proxy rules (Rule 14a-19) for director nominations.","Requires stockholders soliciting proxies to use a non-white proxy card.","Includes technical and conforming changes to reflect updates in Delaware General Corporation Law."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005904","json":"https://secwatch.observer/filing/0001437749-24-005904.json","markdown":"https://secwatch.observer/filing/0001437749-24-005904.md","text":"https://secwatch.observer/filing/0001437749-24-005904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924005904/0001437749-24-005904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924005904/zvra20240228_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:34:34.364591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66742f8fafe2d076e19e00e9bf841357b32a1e33","claim":"ZEVRA THERAPEUTICS, INC.: Amended and restated bylaws effective February 22, 2024 to address universal proxy rules, update stockholder nomination and proposal disclosure, and require proxy card color distinction (effective 2024-02-22).","evidence_excerpt":"On February 22, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”) which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924005904/0001437749-24-005904-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-02-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}